Open AccessPilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine
Author(s) -
Ellen S. Vitetta,
Joan E. Smallshaw,
John Schindler
Publication year - 2012
Publication title -
clinical and vaccine immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.649
H-Index - 77
eISSN - 1556-6811
pISSN - 1556-679X
DOI - 10.1128/cvi.00381-12
Subject(s) - ricin , recombinant dna , adjuvant , clinical trial , virology , toxin , medicine , immunology , biology , microbiology and biotechnology , biochemistry , gene
There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom